SURROGATE ENDPOINTS AS A MEASURE OF DRUG EFFECTS.
A Regulatory Authority′s Opinion About Surrogate Endpoints (R. Temple).
What to Measure in Dementia (L. Whalley & S. Gerhand).
Twenty–foour–hour ambulatory arterial (blood) pressure measurement and the assessment of antihypertensive drug efficacy (J. Hasford, W. Meister).
Potential Measurements in Patients with Osteoporosis (C. Miller).
Are bronchial challenge studies indicators of antiasthmatic activity? (A. J. Frew, S. T. Holgate)
DRUGS AFFECTING BLOOD FLOW TO THE PERIPHERAL CIRCULATION.
Measurements of Blood Rheology for the Evaluation of Pharmacological Agents (G. Nash).
Platelet Function Tests (P. Wyld).
Assessment of the Effects of Drugs on the Peripheral Vasculature (D. Webb & M. Hand).
PRECISION, VALIDITY AND REPRODUCIBILITY OF MEASUREMENT.
Bias and Confounding in Clinical Studies (D. Jones).
What Does Good Clinical Practice Have to Say About Clinical Measurement? (E. Hvidberg).
Measurement of bioequivalence and its relevance to tthe clinical situation (T. Salmonson)
The ′Clinical Trial′ of the Clinical Trial (A. Feinstein).
Patient compliancewith prescribed drug regimens: overview of the past 30 yers of research (j. Urguhart).
MEASUREMENT OF ADVERSE EVENTS.
Prediction of drug interactions: implications of recent advances in drug metabolism (G. T. Tucker).
What number of patients is necessary to establish drug safety? (P. R. Jackson, E. J. Wallis, W. w. Yeo, L E. Ramsay)
Accuracy of adverse data from post–marketing studies and the influence on extension of licensed indications (D. H. Lawson).
Controlled Clinical Trials: Contribution to Drug Safety (M. Langman).
Predicting Adverse Drug Reactions (C. George).
THE EDINBURGH DRUG ABSORPTION FOUNDATION LECTURE.
Interactions in First–Pass Metabolism and Variability in Drug Response (P. Neuvonen).